RxDoctor Payments Data

Hassan Shukri-Mahmod, MD

Neurology · East Syracuse, NYNPI 1366519597

Payments from drug & device makers

$15,310in general payments, 2019–2025

Across 731 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Abbott$2K
  • Biogen$963
  • UCB, Inc.$775
  • EMD Serono, Inc.$755
  • Pfizer$574
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$350%
  • Travel & lodging$1,0507%
  • Food & beverage$14,10492%
  • Education$1211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)174$2,226
Abbott18$1,670
Biogen43$963
UCB, Inc.22$775
EMD Serono, Inc.38$755
Pfizer37$574
Lundbeck LLC20$457
Teva Pharmaceuticals USA, Inc.13$425
SK Life Science, Inc.11$410
Amneal Pharmaceuticals LLC17$397
Lilly USA, LLC19$378
Sanofi19$378
Neurocrine Biosciences, Inc.20$375
Genentech USA, Inc.17$362
Novartis17$355
Amgen(2 entities)14$314
Kyowa Kirin, Inc.13$303
Argenx US, Inc.9$257
AstraZeneca8$253
Supernus Pharmaceuticals, Inc.37$248
Medtronic6$247
TG Therapeutics, Inc.9$240
Otsuka America Pharmaceutical, Inc.11$223
Eisai Inc.8$212
Jazz Pharmaceuticals Inc.6$161
Sunovion Pharmaceuticals Inc.21$160
Averitas Pharma Inc.2$146
MDD US Operations, LLC6$136
Bristol Myers Squibb6$133
Sumitomo Pharma America, Inc.10$110
Acadia Pharmaceuticals Inc7$109
Takeda Pharmaceuticals U.S.A., Inc.4$104
Tanabe Pharma America, Inc.4$92
Johnson & Johnson4$85
Novo Nordisk4$75
Merz Pharmaceuticals, LLC3$69
ANI Pharmaceuticals, Inc.3$68
Impel Pharmaceuticals LLC3$67
Biohaven Pharmaceuticals, Inc.4$65
Vanda Pharmaceuticals Inc.2$63
Mallinckrodt Hospital Products Inc.3$63
Axsome Therapeutics, Inc.2$61
Arbor Pharmaceuticals, Inc.4$57
Biohaven Pharmaceutical Holding Company Ltd.3$54
Xeris Pharmaceuticals, Inc.2$49
Azurity Pharmaceuticals, Inc.2$47
Avanir Pharmaceuticals, Inc.3$41
Acorda Therapeutics, Inc2$41
Neurelis, Inc.1$40
Catalyst Pharmaceuticals, Inc.1$40
Assertio Therapeutics, Inc.2$37
Upsher-smith Laboratories LLC2$36
Grifols USA, LLC1$36
Life Molecular Imaging Ltd1$33
Impel Pharmaceuticals Inc.1$31
Adamas Pharmaceuticals, Inc.2$30
Avion Pharmaceuticals2$25
Banner Life Sciences, LLC1$24
Alnylam Pharmaceuticals Inc.1$22
Promius Pharma LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,310 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$221,675
Medicare patients
660
Services billed
5,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5020$454,235
NuplazidPimavanserin Tartrate17$96,069
Avonex (4 Pack)Interferon Beta-1a11$87,611
Lamictal XrLamotrigine30$48,646
Gamunex-CImmune Globul G/Gly/Iga Avg 4632$46,151
HorizantGabapentin Enacarbil33$45,837
RytaryCarbidopa/Levodopa21$44,551
Aimovig AutoinjectorErenumab-Aooe28$33,620
NuedextaDextromethorphan Hbr/Quinidine15$31,917
Emgality PenGalcanezumab-Gnlm32$31,763
Nurtec OdtRimegepant Sulfate31$31,595
LamictalLamotrigine20$29,527
NourianzIstradefylline14$25,987
Keppra XrLevetiracetam29$22,734
VimpatLacosamide18$21,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$104$454,23520 claims
Acadia Pharmaceuticals IncNuplazid$109$96,06917 claims
BiogenAvonex (4 Pack)$963$87,61111 claims
Grifols USA, LLCGamunex-C$36$46,15132 claims
Arbor Pharmaceuticals, Inc.Horizant$57$45,83733 claims
Amneal Pharmaceuticals LLCRytary$397$44,55121 claims
Avanir Pharmaceuticals, Inc.Nuedexta$41$31,91715 claims
PfizerNurtec Odt$574$31,59531 claims
AbbVieQulipta, Ubrelvy$2,226$29,82926 claims
Kyowa Kirin, Inc.Nourianz$303$25,98714 claims
UCB, Inc.Vimpat$775$21,11918 claims
Sunovion Pharmaceuticals Inc.Aptiom$160$18,02313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →